Tags

Type your tag names separated by a space and hit enter

Targeted broadband ultraviolet b phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study.
Acta Derm Venereol. 2008; 88(4):376-81.AD

Abstract

Narrowband ultraviolet B (NB-UVB) phototherapy, with a 308-nm xenon chloride excimer laser, and targeted UVB phototherapy have produced encouraging therapeutic results for vitiligo. However, very few studies employing broadband UVB exist. Moreover, there has been no direct comparison study between broadband UVB and NB-UVB for the treatment of vitiligo. The aims of this study were to compare the repigmenting efficacy of targeted broadband UVB phototherapy with that of NB-UVB in an equi-erythemogenic manner. Twenty identical vitiliginous lesions from 10 patients were randomly allocated to receive either targeted broadband UVB or targeted NB-UVB phototherapy. UV fluences were started at 50% of the minimal erythema dose detected within the vitiliginous patches, then increased gradually, in the same manner, to ensure equi-erythemogenic comparison. Treatments were carried out twice weekly for 12 weeks. The results show that grade 1, i.e. 1-25% repigmentation, to grade 2, 26-50% repigmentation, occurred in 6 of 10 subjects. Responses in terms of repigmentation, de-pigmentation, or lack thereof, were similar between lesions receiving broadband and NB-UVB phototherapy. Onset of repigmentation occurred as early as 4 weeks of treatment in most subjects. Treatments were well tolerated, with only minimal erythema and hyperpigmentation.

LIMITATIONS

The study was carried out in a small number of patients with skin types III, IV and V. The irradiation device was a targeted UVB device and thus the results may not be applicable to other light sources, such as the excimer laser or total-body irradiation cabinets. In conclusion, targeted broadband UVB produces similar clinical responses to targeted NB-UVB in the treatment of the non-segmental type of vitiligo.

Authors+Show Affiliations

Department of Medicine, Division of Dermatology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. pravit@adsl.loxinfo.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18709309

Citation

Asawanonda, Pravit, et al. "Targeted Broadband Ultraviolet B Phototherapy Produces Similar Responses to Targeted Narrowband Ultraviolet B Phototherapy for Vitiligo: a Randomized, Double-blind Study." Acta Dermato-venereologica, vol. 88, no. 4, 2008, pp. 376-81.
Asawanonda P, Kijluakiat J, Korkij W, et al. Targeted broadband ultraviolet b phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study. Acta Derm Venereol. 2008;88(4):376-81.
Asawanonda, P., Kijluakiat, J., Korkij, W., & Sindhupak, W. (2008). Targeted broadband ultraviolet b phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study. Acta Dermato-venereologica, 88(4), 376-81. https://doi.org/10.2340/00015555-0469
Asawanonda P, et al. Targeted Broadband Ultraviolet B Phototherapy Produces Similar Responses to Targeted Narrowband Ultraviolet B Phototherapy for Vitiligo: a Randomized, Double-blind Study. Acta Derm Venereol. 2008;88(4):376-81. PubMed PMID: 18709309.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeted broadband ultraviolet b phototherapy produces similar responses to targeted narrowband ultraviolet B phototherapy for vitiligo: a randomized, double-blind study. AU - Asawanonda,Pravit, AU - Kijluakiat,Jirasin, AU - Korkij,Wiwat, AU - Sindhupak,Wannasri, PY - 2008/8/19/pubmed PY - 2008/11/15/medline PY - 2008/8/19/entrez SP - 376 EP - 81 JF - Acta dermato-venereologica JO - Acta Derm. Venereol. VL - 88 IS - 4 N2 - UNLABELLED: Narrowband ultraviolet B (NB-UVB) phototherapy, with a 308-nm xenon chloride excimer laser, and targeted UVB phototherapy have produced encouraging therapeutic results for vitiligo. However, very few studies employing broadband UVB exist. Moreover, there has been no direct comparison study between broadband UVB and NB-UVB for the treatment of vitiligo. The aims of this study were to compare the repigmenting efficacy of targeted broadband UVB phototherapy with that of NB-UVB in an equi-erythemogenic manner. Twenty identical vitiliginous lesions from 10 patients were randomly allocated to receive either targeted broadband UVB or targeted NB-UVB phototherapy. UV fluences were started at 50% of the minimal erythema dose detected within the vitiliginous patches, then increased gradually, in the same manner, to ensure equi-erythemogenic comparison. Treatments were carried out twice weekly for 12 weeks. The results show that grade 1, i.e. 1-25% repigmentation, to grade 2, 26-50% repigmentation, occurred in 6 of 10 subjects. Responses in terms of repigmentation, de-pigmentation, or lack thereof, were similar between lesions receiving broadband and NB-UVB phototherapy. Onset of repigmentation occurred as early as 4 weeks of treatment in most subjects. Treatments were well tolerated, with only minimal erythema and hyperpigmentation. LIMITATIONS: The study was carried out in a small number of patients with skin types III, IV and V. The irradiation device was a targeted UVB device and thus the results may not be applicable to other light sources, such as the excimer laser or total-body irradiation cabinets. In conclusion, targeted broadband UVB produces similar clinical responses to targeted NB-UVB in the treatment of the non-segmental type of vitiligo. SN - 0001-5555 UR - https://www.unboundmedicine.com/medline/citation/18709309/Targeted_broadband_ultraviolet_b_phototherapy_produces_similar_responses_to_targeted_narrowband_ultraviolet_B_phototherapy_for_vitiligo:_a_randomized_double_blind_study_ L2 - https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-0469 DB - PRIME DP - Unbound Medicine ER -